Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sukumar Nagendran
AddedMar 31, 2024
UpdatedMay 31, 2026
Sukumar Nagendran

Sukumar Nagendran

Board Member, Taysha Gene Therapies

CrunchbaseLinkedIn

Sukumar Nagendran's Career

Taysha Gene Therapies
Taysha Gene Therapies

Dallas, TX, US

Board Member· Board
Neurogene
Neurogene

New York, NY, US

Board Member· Board
Solid Biosciences
Solid Biosciences

Cambridge, MA, US

Board Member· Board
Medocity
Medocity

Parsippany-Troy Hills, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sukumar Nagendran's Career

Taysha Gene Therapies
Taysha Gene Therapies
Public$468M812020Dallas, TX, US
Board Member· Board

Leadership at Taysha Gene Therapies

Melissa A. EllisMelissa A. EllisBoard Member
Phillip DonenbergPhillip DonenbergBoard Member
Sean NolanSean NolanBoard Member
R A SessionR A SessionFounder
Neurogene
Neurogene
Public$183.5M922018New York City, NY, US
Board Member· Board

Leadership at Neurogene

Srdjan StankovicSrdjan StankovicBoard Member
Robert BaffiRobert BaffiBoard Member
Josephine CruzJosephine CruzCo-Founder
Rachel McMinnRachel McMinnCo-Founder
Dr Stephen R BiggarDr Stephen R BiggarBoard Member
Serge StankovicSerge StankovicBoard Member

Similar to Neurogene

NeuroGenetic PharmaceuticalsNeuroGenetic PharmaceuticalsDel Mar, CA, USDrugs, Pharmaceuticalsest. 2009NeuroGenetic PharmaceuticalsDel Mar, CA, US · est. 2009

US-based NeuroGenetic Pharmaceuticals pioneers in developing innovative drugs to prevent neurodegenerative diseases.

Seed · $4M9
Empyrean NeuroscienceEmpyrean NeuroscienceNew York City, NY, USGenetic Therapiesest. 2019Empyrean NeuroscienceNew York City, NY, US · est. 2019

Empyrean: Revolutionizing healthcare with genetic engineering for severe neurological disorders.

Series A · $22M11
NeuralyNeuralyGermantown, MD, USTherapeuticsest. 2016NeuralyGermantown, MD, US · est. 2016

Neuraly, Inc.: A biotech firm developing neuro-protective therapies for neurological disorders.

Series A · $36M125
NeuroviaNeuroviaSan Francisco, CA, USDrugs, Therapeuticsest. 2013NeuroviaSan Francisco, CA, US · est. 2013

NeuroVia, Inc.: A US-based biopharmaceutical company developing therapies for neurological diseases.

Public · $14M75
Solid Biosciences
Solid Biosciences
Public$441.3M872013Cambridge, MA, US
Board Member· Board

Leadership at Solid Biosciences

Adam StoneAdam StoneBoard Member
Matt ArnoldMatt ArnoldBoard Member
Martin FreedMartin FreedBoard Member
Rajeev ShahRajeev ShahBoard Member
Lynne SullivanLynne SullivanBoard Member
Bo CumboBo CumboCEO

Similar to Solid Biosciences

SonoTheraSonoTheraSouth San Francisco, CA, USGenetic Therapiesest. 2021SonoTheraSouth San Francisco, CA, US · est. 2021

SonoThera is a biotechnology company developing ultrasound-mediated nonviral genetic medicines for diseases including Duchenne muscular dystrophy and hemophilia A.

Series B · $185.8M50
Sarepta TherapeuticsSarepta TherapeuticsCambridge, MA, USGene Therapiesest. 1980Sarepta TherapeuticsCambridge, MA, US · est. 1980

Sarepta Therapeutics, a US-based biopharmaceutical firm, specializes in medical research and drug development.

Public · $1.4B1.2k
Cogent BiosciencesCogent BiosciencesWaltham, MA, USBiotech, Therapiesest. 2014Cogent BiosciencesWaltham, MA, US · est. 2014

US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.

Public · $692.7M138
bluebird biobluebird bioCambridge, MA, USGene Therapiesest. 1992bluebird bioCambridge, MA, US · est. 1992

Bluebird Bio, Inc.: A US-based biotech firm offering gene therapies for severe genetic disorders.

Public · $3.4B323
Medocity
Medocity
Series A$19.4M582013Parsippany-Troy Hills, NJ, US
Board Member· Board

Leadership at Medocity

Suresh KumarSuresh KumarBoard Member
Raj AgarwalRaj AgarwalCo-Founder
Anil BalaniAnil BalaniCo-Founder
Rajesh GargRajesh GargBoard Member

Sukumar Nagendran's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Sukumar Nagendran

Bob MoreBob MoreBoard Member · Nuon TherapeuticsMara AspinallMara AspinallBoard Member · GenePeeksSamarth KulkarniSamarth KulkarniBoard Member · Black Diamond TherapeuticsAkshay VaishnawAkshay VaishnawBoard Member · Scholar Rock Holding